Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Year-over-year operating cash flow growth rate
| Period | Value |
|---|---|
| Q4 2025 | 250.22% |
| Q3 2025 | -17.14% |
| Q2 2025 | 161.91% |
| Q1 2025 | -189.62% |
| Q4 2024 | -22.06% |
| Q3 2024 | 174.37% |
| Q2 2024 | -28.77% |
| Q1 2024 | 162.66% |
| Q4 2023 | -6.93% |
| Q3 2023 | 9424.39% |
| Q2 2023 | -100.24% |
| Q1 2023 | -36.51% |
| Q4 2022 | 160.98% |
| Q3 2022 | 72.50% |
| Q2 2022 | -77.16% |
| Q1 2022 | 88.16% |
| Q4 2021 | 38.04% |
| Q3 2021 | -1.73% |
| Q2 2021 | 89.48% |
| Q1 2021 | 1902.61% |
| Q4 2020 | -95.79% |
| Q3 2020 | -47.73% |
| Q2 2020 | 44.08% |
| Q1 2020 | 330.58% |
| Q4 2019 | -18.43% |
| Q3 2019 | 89.85% |
| Q2 2019 | -234.91% |
| Q1 2019 | 38.95% |
| Q4 2018 | 20.27% |
| Q3 2018 | -63.23% |
| Q2 2018 | 21.20% |
| Q1 2018 | 94.06% |
| Q4 2017 | 13.24% |
| Q3 2017 | 166.22% |
| Q2 2017 | -57.12% |
| Q1 2017 | 15.38% |
| Q4 2016 | 13.33% |
| Q3 2016 | 78.60% |
| Q2 2016 | -20.92% |
| Q1 2016 | -4.03% |